Teva Historical Income Statement

TEVA Stock  USD 13.98  0.07  0.50%   
Historical analysis of Teva Pharma income statement accounts such as Other Operating Expenses of 7.6 B, Operating Income of 732.2 M, EBIT of 411.4 M or Ebitda of 411.4 M can show how well Teva Pharma Industries performed in making a profits. Evaluating Teva Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Teva Pharma's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Teva Pharma Industries latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Teva Pharma Industries is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

About Teva Income Statement Analysis

Teva Pharma Industries Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Teva Pharma shareholders. The income statement also shows Teva investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Teva Pharma Income Statement Chart

Teva Pharma Industries Income Statement is one of the three primary financial statements used for reporting Teva's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Teva Pharma Industries revenue and expense. Teva Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Teva Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 732.2 M, whereas Depreciation And Amortization is forecasted to decline to about 667.3 M.

Total Revenue

Total revenue comprises all receipts Teva Pharma Industries generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Teva Pharma Industries minus its cost of goods sold. It is profit before Teva Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most accounts from Teva Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
At present, Teva Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 732.2 M, whereas Depreciation And Amortization is forecasted to decline to about 667.3 M.
 2021 2023 2024 (projected)
Interest Expense1.1B1.0B1.1B
Depreciation And Amortization1.3B1.2B667.3M

Teva Pharma income statement Correlations

0.270.820.770.83-0.360.540.710.820.8-0.36-0.51-0.36-0.280.750.740.010.68-0.420.32-0.310.110.030.20.160.16
0.270.280.210.3-0.110.070.080.350.21-0.29-0.27-0.31-0.080.350.590.360.13-0.420.47-0.410.68-0.61-0.54-0.33-0.55
0.820.280.970.99-0.150.720.790.960.99-0.14-0.34-0.15-0.080.90.830.20.86-0.240.19-0.160.00.180.290.270.22
0.770.210.970.94-0.070.750.790.880.99-0.02-0.23-0.030.060.930.760.30.9-0.110.080.0-0.190.340.40.280.38
0.830.30.990.94-0.190.690.770.990.97-0.2-0.39-0.2-0.150.880.850.160.83-0.30.24-0.220.080.120.260.270.16
-0.36-0.11-0.15-0.07-0.190.09-0.05-0.23-0.130.910.870.910.85-0.27-0.170.22-0.080.87-0.860.79-0.330.2-0.180.03-0.17
0.540.070.720.750.690.090.960.650.720.0-0.24-0.010.030.620.480.180.59-0.070.010.01-0.240.410.370.580.32
0.710.080.790.790.77-0.050.960.730.79-0.12-0.36-0.12-0.070.70.540.130.63-0.170.07-0.08-0.20.390.430.580.34
0.820.350.960.880.99-0.230.650.730.91-0.27-0.45-0.27-0.230.810.850.070.75-0.370.3-0.320.22-0.010.160.240.02
0.80.210.990.990.97-0.130.720.790.91-0.08-0.29-0.09-0.010.940.790.280.9-0.170.12-0.06-0.140.310.40.290.35
-0.36-0.29-0.14-0.02-0.20.910.0-0.12-0.27-0.080.971.00.92-0.2-0.240.250.030.98-0.940.94-0.560.40.05-0.080.1
-0.51-0.27-0.34-0.23-0.390.87-0.24-0.36-0.45-0.290.970.970.88-0.37-0.370.21-0.150.96-0.90.9-0.460.27-0.08-0.23-0.01
-0.36-0.31-0.15-0.03-0.20.91-0.01-0.12-0.27-0.091.00.970.9-0.21-0.250.230.030.98-0.940.94-0.550.40.04-0.090.09
-0.28-0.08-0.080.06-0.150.850.03-0.07-0.23-0.010.920.880.9-0.04-0.180.40.050.87-0.830.91-0.510.390.090.00.12
0.750.350.90.930.88-0.270.620.70.810.94-0.2-0.37-0.21-0.040.740.480.86-0.290.26-0.14-0.110.290.430.240.41
0.740.590.830.760.85-0.170.480.540.850.79-0.24-0.37-0.25-0.180.740.070.76-0.370.35-0.350.34-0.26-0.11-0.07-0.18
0.010.360.20.30.160.220.180.130.070.280.250.210.230.40.480.070.250.2-0.140.3-0.230.340.180.050.29
0.680.130.860.90.83-0.080.590.630.750.90.03-0.150.030.050.860.760.25-0.050.050.05-0.260.290.370.110.38
-0.42-0.42-0.24-0.11-0.30.87-0.07-0.17-0.37-0.170.980.960.980.87-0.29-0.370.2-0.05-0.960.96-0.630.470.11-0.050.17
0.320.470.190.080.24-0.860.010.070.30.12-0.94-0.9-0.94-0.830.260.35-0.140.05-0.96-0.930.64-0.52-0.22-0.12-0.19
-0.31-0.41-0.160.0-0.220.790.01-0.08-0.32-0.060.940.90.940.91-0.14-0.350.30.050.96-0.93-0.730.590.270.080.33
0.110.680.0-0.190.08-0.33-0.24-0.20.22-0.14-0.56-0.46-0.55-0.51-0.110.34-0.23-0.26-0.630.64-0.73-0.92-0.75-0.36-0.84
0.03-0.610.180.340.120.20.410.39-0.010.310.40.270.40.390.29-0.260.340.290.47-0.520.59-0.920.880.570.9
0.2-0.540.290.40.26-0.180.370.430.160.40.05-0.080.040.090.43-0.110.180.370.11-0.220.27-0.750.880.640.89
0.16-0.330.270.280.270.030.580.580.240.29-0.08-0.23-0.090.00.24-0.070.050.11-0.05-0.120.08-0.360.570.640.43
0.16-0.550.220.380.16-0.170.320.340.020.350.1-0.010.090.120.41-0.180.290.380.17-0.190.33-0.840.90.890.43
Click cells to compare fundamentals

Teva Pharma Account Relationship Matchups

Teva Pharma income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization1.8B416M1.6B1.3B1.2B667.3M
Interest Expense822M963M1.1B966M1.0B1.1B
Total Revenue16.9B16.7B15.9B14.9B15.8B9.5B
Gross Profit7.5B7.7B7.6B7.0B7.6B4.8B
Other Operating Expenses14.2B13.6B12.8B12.2B12.7B7.6B
Operating Income(1.6B)2.8B3.1B3.2B433M732.2M
Ebit1.3B2.8B3.1B3.2B433M411.4M
Ebitda3.2B4.6B4.5B4.1B433M411.4M
Cost Of Revenue9.4B8.9B8.3B8.0B8.2B4.7B
Total Operating Expenses4.8B4.7B4.5B4.3B4.5B2.9B
Income Before Tax(1.3B)(4.4B)658M(3.1B)(624M)(592.8M)
Total Other Income Expense Net(4.1B)(7.5B)(2.5B)(5.9B)(1.1B)(1.1B)
Net Income(999M)(4.0B)417M(2.4B)(559M)(531.1M)
Income Tax Expense(278M)(168M)211M(638M)(65M)(61.8M)
Research Development1.0B997M967M838M953M809.2M
Selling General Administrative1.2B1.2B1.1B1.2B1.2B1.2B
Net Income Applicable To Common Shares(999M)(4.0B)417M(2.4B)(2.1B)(2.0B)
Minority Interest(2M)(109M)39M53M56M74.7M
Selling And Marketing Expenses2.6B2.5B2.4B2.3B2.3B3.2B
Net Income From Continuing Ops(987M)(4.2B)447M(2.4B)(615M)(645.8M)
Tax Provision(278M)(168M)211M(638M)(7M)(7.4M)
Net Interest Income(877M)(963M)(962M)(966M)(1.1B)(1.1B)
Reconciled Depreciation1.7B1.6B1.3B1.3B1.2B1.3B
Non Operating Income Net Other(1.0B)(835M)(696M)(1.0B)(1.2B)(1.3B)

Currently Active Assets on Macroaxis

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Teva Stock analysis

When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.50)
Revenue Per Share
14.161
Quarterly Revenue Growth
0.148
Return On Assets
0.0454
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.